Ergebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI
|
|
- Walter Jefferson
- 5 years ago
- Views:
Transcription
1 Ergebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI
2 NAT for cellular blood components in Germany Definition of minimal NAT sensitivity limit (ID) HCV-NAT IU / ml ( = cps / ml) HIV1-NAT IU / ml ( = cps / ml)
3 Evolution of NAT systems in-house NATs Cobas Amplicor HCV Cobas Amplicor HCV v2.0 Procleix HCV/HIV Cobas AmpliScreen HCV, HIV, HBV Procleix Ultrio Assay Procleix TIGRIS System with the Ultrio Cobas S201 with TaqScreen
4 Procleix with the Ultrio
5 Cobas S201 with TaqScreen configuration 1/2/1 Pooling Manager Workstation AmpliLink Workstation Hamilton Microlab STAR Pipettor Data Manager Workstation COBAS AmpliPrep Instrument COBAS TaqMan Analyzer Reporting of Results
6 European Countries Leading Pool size by country Pool size Pool of 1 ( Chiron ) Pool < 10 ( Roche ) Pool > 10 or unknown No NAT in routine Other countries: South Africa Israël Russia Egypt
7 NAT for cellular blood components in Germany Mandatory NATs for all blood / plasma donations Definition of minimal NAT sensitivity limit (ID) HCV-NAT IU / ml ( = cps / ml) HIV1-NAT IU / ml ( = cps / ml) NAT yield versus breakthrough transmissions??
8
9 Viremia during the "diagnostic window" HCV HCV-RNA (copies / ml) 1,0E+10 1,0E+09 1,0E+08 1,0E+07 1,0E+06 1,0E+05 1,0E+04 1,0E+03 1,0E+02 1,0E+01 HCV-RNA doubling time 10,8 h IU / ml 1,0E Days after infection HCV-infection antihcv pos antihcv negative phase
10 NAT onlies: HCV 92 HCV-NAT onlies = 1 / donations -2007) Nübling et al. (2009) Transfusion 49,
11 92 HCV-NAT onlies = 1 / donations NAT onlies incidence centers #47 6 / donations = 1 / #15 16 / donations = 1 / #08 9 / donations = 1 / Lower incidence centers #30 4 / donations = 1 / #52 6 / donations = 1 / #23 0 / donations = 0 /
12 Viral Loads in HCV NAT Yield Cases 40 yield cases with viral load data 39 (99%) >> IU/ml 1,00E+08 1,00E+07 Viral Load (IU/mL) 1,00E+06 1,00E+05 1,00E+04 1,00E+03 1,00E+02 1,00E+01 1,00E IU / ml Nübling et al. (2009) Transfusion 49,
13 HCV genotypes in NAT Yield Cases 26 yield cases with HCV genotype data HCV gt 1 50% HCV gt 3 38% HCV gt 2 12%
14 Transfusion-associated HCV transmissions Cases reported to PEI Introduction of NAT HCV Transmissions Year missed by AmpliScreen HCV /
15 HCV transmission repeat donor: seroconversion (antihcv, HCV- HCV genotype 2b look-back previous donation antihcv (Ortho 3.0) neg HCV-RNA (AmpliScreen/24) neg recipient (erythrocytes) HCV-pos HCV genotype 2b plasma still available replicate testing (n=5) in all available NAT systems
16 HCV transmission HCV window phase, genotype 2b 95% LOD (WHO IS, gt1) pos results (ID) Cobas Amplicor 43 IU/ml 1 / 5 Cobas AmpliScreen HCV Test v IU/ml 1 / 5 HPS Cobas TaqMan HCV Test 15 IU/ml 3 / 5 CAP Cobas Amplicor HCV Test v IU/ml 3 / 5 CAP Cobas TaqMan HCV Test 13 IU/ml 3 / 5 CAP Cobas TaqScreen 11 IU/ml 5 / 5 Procleix HIV-1/HCV Assay 2 IU/ml 0 / 5 Procleix Ultrio Assay 3 IU/ml 2 / 5 Versant HCV RNA Qual 10 IU/ml 0 / 5 Abbott RealTime HCV 11 IU/ml 4 / 5 Kretzschmar et al. (2007) Vox Sanguinis 92,
17
18 Viremia during the "diagnostic window" HIV-1 HIV-RNA (copies / ml) 1,0E+10 1,0E+09 1,0E+08 1,0E+07 1,0E+06 1,0E+05 1,0E+04 1,0E+03 1,0E+02 1,0E+01 1,0E+00 HIV1-RNA doubling time 21,5 h p24-positive p24-negative Days after infection IU / ml HIV-infection antihiv-negative phase antihiv pos
19 NAT onlies: HIV 11 HIV-NAT onlies among 19 million donations ( ) = 1 / donations (17 HIV-NAT onlies from 1999 to 2007 = 1 / donations) Nübling et al. (2009) Transfusion 49,
20 11 yield cases with viral load data 10 > IU/ml 1,00E+08 1,00E+07 1,00E+06 Viral Load (IU/mL) 1,00E+05 1,00E+04 1,00E+03 1,00E+02 10,000 IU/ml 1,00E+01 1,00E+00 Nübling et al. (2009) Transfusion 49,
21 Transfusion-associated HIV transmissions Cases reported to PEI Introduction of HIV NAT
22 HIV transmission repeat donor: seroconversion (antihiv1/2) HIV1 subtype B look-back previous donation antihiv1/2 neg HIV1- neg recipient (erythrocytes) HIV1-seroconversion HIV1 subtype B, same variant as in donor -up sample 147 IU/ml ID CAP CTM HIV Ag/Ab test negative (Abbott)
23 back-up sample HIV transmission 147 IU/ml ID CAP CTM HIV HIV Ag/Ab test negative (Abbott) recovered plasma into manufacturing pool: HIV1-RNA neg repeat donor: seroconversion (antihiv1/2) quantitative HIV-NATs screening HIV-NATs CAP CTM HIV (IU/ml) HPS CTM HIV (IU/ml) CAM HIV (IU/ml) Abbott RealTime HIV-1 (IU/ml) Procleix Ultrio Cobas AmpliScreen HIV (MP) Cobas TaqScreen neg neg <LLQ 924 pos () pos (2/2) pos
24 HIV-1 subtype B Transmission ) 100 fold underdetection of virus variant in routine NAT Sense primer CAP CTM HIV-1 Test (nt 1788 nt 1819) CTM Primer: 5 AGT GGG GGG ACA TCA AGC AGC CAT GCA AA 3 Donor: 5 AGT GGG GGG ACA TCA AGC AGC CAT GCA AA 3 Probe CAP CTM HIV-1 Test (nt 1821 nt 1856) CTM Probe: 5 TCT GCA GCT TCC TCA TTG ATG GT A TCT TTT AAC 3 Donor: 5 TCT GCA GCT TCC TCA TTG ATG GT T TCT TTT AAC 3 Antisense primer CAP CTM HIV-1 Test (nt 1921 nt 1950) CTM Primer: 5 G G T ACT AGT AGT TCC TGC TAT GTC ACT T CC 3 Donor: 5 G T T ACT AGT AGT TCC TGC TAT GTC ACT A CC 3 24 Schmidt et al. (2009) Transfusion 49,
25
26 HBV : early infection phase IU/ml DNA t x2 =48 h HBsAg Pool NAT ID NAT antihbc weeks
27
28 HBV : early infection + low level carrrier phase IU/ml 10 9 introduction of antihbc (Oct 1, 2006) 2% antihbc pos DNA HBsAg antihbc weeks years
29 HBV-DNA detection in antihbc (+) HBV-DNA (+) Donor # % DNApos 95% LOD Screening HBV-NATs CAP / Cobas TaqScreen 3/5 62% 4 IU/ml (30) AmpliScreen HBV (MP) 3/5 3/5 44% 5 IU/ml (22/50) Procleix Ultrio 3/5 3/5 26% 7 IU/ml (13/50) Procleix Ultrio Plus 2/5 2/5 2/5 52% 1,9 IU/ml (26/50)
30 Screening HBV-NATs HBV-DNA detection in antihbc (+) HBV-DNA (+) Donor # % DNApos 95% LOD CAP / Cobas TaqScreen 3/5 62% 4 IU/ml (30) AmpliScreen HBV (MP) 3/5 3/5 44% (22/50) 5 IU/ml Procleix Ultrio Assay 3/5 3/5 26% 7 IU/ml (13/50) Procleix Ultrio Plus 2/5 2/5 2/5 52% 1,9 IU/ml (26/50) Diagnostic qt NATs artus HBV TaqMan PCR 2/5 3/5 42% (20) 4 IU/ml HPS / Cobas TaqMan 3/5 64% 5 IU/ml (32/50) Abbott RealTime 3/5 66% 6 IU/ml (33/50) artus HBV LC PCR 3/5 3/5 50% (20) 6 IU/ml CAP / Cobas TaqMan 2/5 2/5 3/5 42% 12 IU/ml (20)
31 Zusammenfassung S NAT: Hohe Virussicherheit bei Plasma- und Blutprodukten S ären Blutkomponenten unvermeidlich low level viremia mismatch S Weiterer Handlungsbedarf bei HBV?
32 VIELEN DANK an... S S Dr Evelyne Kretzschmar, Duisburg S PD Dr Michael Schmidt, Frankfurt FG 2/4 Molekulare Virologie S Ines Amberg S Dr Michael Chudy S Christine Hanker-Dusel S Claudia König S Magdalene Köstermenke S Dr Julia Kress S Christine Pfannkuch
Update from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012
Update from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012 SOGAT XXIV Ljubljana, 8-9 May 2013 2012 ISS EQAs for NAT ISS EQA Tri-NAT (HCV,
More informationCALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD
CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD AAJ van Drimmelen, E.R. Bax and W.G.V. Quint, BioQControl (BQC), Delft Diagnostic Laboratories
More informationNAT Screening of Blood Donations in NBC, TRCS
IPFA/PEI, Italy NAT Screening of Blood Donations in NBC, TRCS 2000-2001 Clinical evaluation using COBAS AmpliiScreen HIV & HCV assays, (MP24) window period rate - 1 : 108,768 for HIV-1 and HCV 2002 Routine
More informationKhalid Alquthami (Correspondence) Regional Lab, Makkah. Saudi Arabia
1 Regional Lab, Makkah. Saudi Arabia stract: Clinical specificity and genotype/subtype detection of viruses using the Cobas TaqScreen MPX system V 2.0, which is a nucleic acid test (NAT) that uses multiples
More informationCalibration and stability of WHO and secondary viral standards
Calibration and stability of WHO and secondary viral standards Nico Lelie, Harry van Drimmelen and the International NAT Study Group Facilities DDL Diagnostic Laboratories Outline Calibration of WHO and
More informationImpact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Overview of SANBS SANBS is a private not for profit company
More informationHEPATITIS SCREENING IN THE LITHUANIAN BLOOD ESTABLISHMENTS. Joana Bikulčienė Director of National blood center
HEPATITIS SCREENING IN THE LITHUANIAN BLOOD ESTABLISHMENTS Joana Bikulčienė Director of National blood center j.bikulciene@kraujodonoryste.lt Organizational structure of Lithuanian blood service 1 specialized
More informationImpact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening
Impact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening IPFA Lisbon 216 Marion Vermeulen Disclaimer Race classifications are described as
More informationFrequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India.
Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Cinzia Keechilot, Veena Shenoy 1,V Anil kumar 2,Lalita Biswas 3. MBBS student * Transfusion
More informationQuantification of HBV, HCV genotype and HIV subtype panels
Quantification of HBV, HCV genotype and HIV subtype panels Harry van Drimmelen 1,2, Wim Quint 2, Nico Lelie 3 and the international NAT study group 1. Biologicals Quality Control, 2. DDL Diagnostic Laboratory,
More informationrisk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV)
Prevention and ResidualR risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Syria Laperche L (Centre National de référence r rence pour les hépatites h B et C en Transfusion)
More informationRoutine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors
Journal of the Egyptian Society of Haematology & Research, Vol. 7, No. 2, September: 1-5, 2011 Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors HISHAM
More informationImpact of multi-dye multiplex technology on testing algorithm
Impact of multi-dye multiplex technology on testing algorithm Lydia Blanco. Mª Isabel Gonzalez-Fraile Centro de Hemoterapia y Hemodonación de Castilla y León, España TTI EPIDEMIOLOGICAL DATA IN SPAIN NAT
More informationEvaluation of run controls for cobas 6800 MPX and HEV assay
Evaluation of run controls for cobas 6800 MPX and HEV assay Marco Koppelman Head of Nucleic Acid testing (NAT) laboratory, National Screening laboratory of Sanquin (NSS) in the Netherlands Satellite Meeting
More informationSupplementary Figure 1
Supplementary Figure 1 Supplementary Figure 1: Cryopreservation alters CD62L expression by CD4 T cells. Freshly isolated (left) or cryopreserved PBMCs (right) were stained with the mix of antibodies described
More informationNAT / BLOOD SCREENING - PRODUCT RANGE
NAT / BLOOD SCREENING - PRODUCT RANGE QC Sample Name Analytes Assay / Instrument Page QConnect TriScreen Roche cobas TaqScreen MPX Test, v 2.0 (s201) Roche cobas MPX Test (6800/8800) QConnect Grifols Ultrio
More informationDEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE
DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE SoGAT Clinical Diagnostics III 12-13 January 2011, London Michael Chudy Julia Kreß Micha Nübling Paul-Ehrlich-Institut
More informationHEV Assay Development Update
HEV Assay Development Update Jeffrey M. Linnen, Ph.D. Senior Director, Research & Development Hologic Gen-Probe, San Diego, California USA IPFA/PEI 20th International Workshop on Surveillance and Screening
More informationSupplementary Table 3. 3 UTR primer sequences. Primer sequences used to amplify and clone the 3 UTR of each indicated gene are listed.
Supplemental Figure 1. DLKI-DIO3 mirna/mrna complementarity. Complementarity between the indicated DLK1-DIO3 cluster mirnas and the UTR of SOX2, SOX9, HIF1A, ZEB1, ZEB2, STAT3 and CDH1with mirsvr and PhastCons
More informationWHO Parvovirus B19 Genotype Panel
WHO Parvovirus B19 Genotype Panel Mei-ying W Yu, PhD SoGAT XXII Rome, 14-15 April 2011 1 st WHO International Reference Panel for Parvovirus B19 Genotypes In Oct 2009, a plasma-derived parvovirus B19 (B19V)
More informationAccuVert HBV Seroconversion Panel PHM941(M) ( )
PACKAGE INSERT PHM941(M) (0605-0061) INTENDED USE PHM941(M) (0605-0061) is a group of serial bleeds from an individual plasma donor during HBV seroconversion. This panel is intended for use by diagnostics
More informationChallenges in HBV detec1on in blood donors
Challenges in HBV detec1on in blood donors Jean- Pierre Allain Dept Haematology, University of Cambridge, UK Phylogene1c analysis of human and ape HBV over 1me of evolu1on (Pareskevis et al, Hepatology
More informationTrends in molecular diagnostics
Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling
More informationStandardization: Calibration of. International Standards, reference preparations and working standards. Micha Nübling, PEI
Standardization: Calibration of International Standards, reference preparations and working standards Micha Nübling, PEI Paul-Ehrlich-Institut Governmental Authority for biological medicinal products Blood
More informationStability of native, lyophilized and inactivated standards
Stability of native, lyophilized and inactivated standards Harry van Drimmelen Bio Quality Control, Heiloo, Netherlands Satellite Meeting before IPFA-PEI 25 th Workshop Twenty-five Years Standardization
More informationDonor Screening in The Region. Vincini GA NRL, Melbourne, Australia
Donor Screening in The Region Vincini GA NRL, Melbourne, Australia NRL Established in 1985 Not-for-profit organisation that exists to support laboratories that perform testing for the diagnosis and management
More informationSupplemental Data. Shin et al. Plant Cell. (2012) /tpc YFP N
MYC YFP N PIF5 YFP C N-TIC TIC Supplemental Data. Shin et al. Plant Cell. ()..5/tpc..95 Supplemental Figure. TIC interacts with MYC in the nucleus. Bimolecular fluorescence complementation assay using
More informationInstruction to implement measures for risk minimisation in using HIV-1 NAT test systems
Paul-Ehrlich-Institut P.O. Box 63207 Langen, Germany To: The marketing authorisation holders of cellular blood products and fresh frozen plasma and the holders of authorisations for stem cell preparations
More informationPROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA
PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA SoGAT Clinical Diagnostics II 30 September / 1 October 2009, Istanbul Michael Chudy Julia Kreß C. Micha
More informationNational Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands. TransMed conference Bhopal 18 November 2016
Dr. Anton van Weert National Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands TransMed conference Bhopal 18 Introduction Thank you! Anton van Weert, PhD, MBA Manager
More informationHepatitis C Virus (RNA)A
Hepatitis C Virus (RNA)A 2012 EQA Programme Final Report QAV994112 (HCVRNA12A) Professor Jacques Izopet Scientific Expert on behalf of QCMD Report authorised by the QCMD Executive in July 2012 A UKAS accredited
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Sherman SI, Wirth LJ, Droz J-P, et al. Motesanib diphosphate
More informationTable S1. Oligonucleotides used for the in-house RT-PCR assays targeting the M, H7 or N9. Assay (s) Target Name Sequence (5 3 ) Comments
SUPPLEMENTAL INFORMATION 2 3 Table S. Oligonucleotides used for the in-house RT-PCR assays targeting the M, H7 or N9 genes. Assay (s) Target Name Sequence (5 3 ) Comments CDC M InfA Forward (NS), CDC M
More informationDiagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)
Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves
More informationExperience with Standardisation of Blood Virology NAT. Clare Morris Division of Retrovirology National Institute for Biological Standards and Control
Experience with Standardisation of Blood Virology NAT Clare Morris Division of Retrovirology National Institute for Biological Standards and Control Background of Blood Virology Standardisation In the
More informationToluidin-Staining of mast cells Ear tissue was fixed with Carnoy (60% ethanol, 30% chloroform, 10% acetic acid) overnight at 4 C, afterwards
Toluidin-Staining of mast cells Ear tissue was fixed with Carnoy (60% ethanol, 30% chloroform, 10% acetic acid) overnight at 4 C, afterwards incubated in 100 % ethanol overnight at 4 C and embedded in
More informationQUANTITATION OF HEPATITIS B VIRUS DNA IN PLASMA USING A SENSITIVE COST-EFFECTIVE IN-HOUSE REAL-TIME PCR ASSAY
Indian Journal of Medical Microbiology, (2009) 27(2): 111-5 Original Article QUANTITATION OF HEPATITIS B VIRUS DNA IN PLASMA USING A SENSITIVE COST-EFFECTIVE IN-HOUSE REAL-TIME PCR ASSAY Hubert Darius
More informationHBV-DNA reference panels
HBV-DNA reference panels The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Overview HBV-DNA panels
More informationa) Primary cultures derived from the pancreas of an 11-week-old Pdx1-Cre; K-MADM-p53
1 2 3 4 5 6 7 8 9 10 Supplementary Figure 1. Induction of p53 LOH by MADM. a) Primary cultures derived from the pancreas of an 11-week-old Pdx1-Cre; K-MADM-p53 mouse revealed increased p53 KO/KO (green,
More informationSupplementary Document
Supplementary Document 1. Supplementary Table legends 2. Supplementary Figure legends 3. Supplementary Tables 4. Supplementary Figures 5. Supplementary References 1. Supplementary Table legends Suppl.
More informationNon-competitive Internal Control Concept for PCR-based Qualitative Assays
Christian O. Simon Roche Molecular Diagnostics Rotkreuz, CH Non-competitive Internal Control Concept for PCR-based Qualitative Assays 23 rd SoGAT Meeting, 16 th 17 th April, 2012, Vilnius, Lithuania Design
More informationThe Technical Aspects of Pathogen Testing in Canada. Nancy Angus Canadian Blood Services Director, Testing
PERMISSON TO USE: Please note that, by making their presentations available on-line, primary authors have agreed to share their presentations. However, should you want to use some of the data or slides
More informationFor information only: all participants in the graduated plan procedure. 7 January 2013
Paul-Ehrlich-Institut P.O. Box 63207 Langen, Germany To: All marketing authorisation holders of cellular blood products and therapeutic single plasma as well as holders of an authorisation for stem cells
More informationc Tuj1(-) apoptotic live 1 DIV 2 DIV 1 DIV 2 DIV Tuj1(+) Tuj1/GFP/DAPI Tuj1 DAPI GFP
Supplementary Figure 1 Establishment of the gain- and loss-of-function experiments and cell survival assays. a Relative expression of mature mir-484 30 20 10 0 **** **** NCP mir- 484P NCP mir- 484P b Relative
More informationExternal Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience
External Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience Giulio Pisani Biologicals Unit CRIVIB, ISS, Rome SOGAT XXII 14 th 15 th April 2011 - Istituto Superiore di
More informationHuman diagnostics. Better be Sure: Quantify HDV & HBV viral load. RoboGene product family
Human diagnostics Better be Sure: Quantify HDV & HBV viral load. RoboGene product family 2 RoboGene Product Family Improved patient management: Standardized monitoring of HBV DNA and HDV RNA viral load.
More informationWHO Prequalification of Diagnostics Programme PUBLIC REPORT
WHO Prequalification of Diagnostics Programme PUBLIC REPORT Product: COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, version 2.0 (TaqMan 48) Number: PQDx 0126-046-00 Abstract The COBAS AmpliPrep/COBAS TaqMan
More informationEvolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention
Evolution of HIV Diagnostics and Goals for the 2010 Conference Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics CDC Division of HIV/AIDS Prevention Evolution or other influences like
More informationCD31 5'-AGA GAC GGT CTT GTC GCA GT-3' 5 ' -TAC TGG GCT TCG AGA GCA GT-3'
Table S1. The primer sets used for real-time RT-PCR analysis. Gene Forward Reverse VEGF PDGFB TGF-β MCP-1 5'-GTT GCA GCA TGA ATC TGA GG-3' 5'-GGA GAC TCT TCG AGG AGC ACT T-3' 5'-GAA TCA GGC ATC GAG AGA
More informationtransfusion-transmissible HCV and HIV in Italy Haemovigilance and the residual risk of
Haemovigilance and the residual risk of transfusion-transmissible Giuliano Grazzini, MD National Blood Centre, National Institute of Health, Rome, Italy & International Federation of Blood Donor Organizations
More informationAccuSet HBV Worldwide Performance Panel
PACKAGE INSERT 0805-033 INTENDED USE The is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot HBV test methods. Characterized samples
More informationNRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens
NRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens Vincini GA*, Cabuang LM, Land S, Best SJ NRL London, 12 January 2011 NRL EQAS for NAT HCV Genotyping
More informationCustomer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands
PRODUCT CATALOGUE Customer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands Communication +31 72 202 07 30 +31 72 202 07 31 sales@bioqcontrol.com
More informationCharacterizing intra-host influenza virus populations to predict emergence
Characterizing intra-host influenza virus populations to predict emergence June 12, 2012 Forum on Microbial Threats Washington, DC Elodie Ghedin Center for Vaccine Research Dept. Computational & Systems
More informationSupplementary Materials
Supplementary Materials 1 Supplementary Table 1. List of primers used for quantitative PCR analysis. Gene name Gene symbol Accession IDs Sequence range Product Primer sequences size (bp) β-actin Actb gi
More informationHepa%%s E Virus Is it a Concern?
IPFA/PEI 17 th Workshop on Surveillance and Screening of Blood Borne Pathogens 26-27 May 2010, The Regent Esplanade Zagreb Hotel, Zagreb, Croa%a Hepa%%s E Virus Is it a Concern? Keiji Matsubayashi Hokkaido
More informationNature Structural & Molecular Biology: doi: /nsmb Supplementary Figure 1
Supplementary Figure 1 U1 inhibition causes a shift of RNA-seq reads from exons to introns. (a) Evidence for the high purity of 4-shU-labeled RNAs used for RNA-seq. HeLa cells transfected with control
More informationHIV-RNA reference panels
The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Overview HIV-RNA panels for sensitivity analysis...
More informationCustomer Service and Ordering Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands
PRODUCT CATALOGUE Customer Service and Ordering Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands Communication +31 72 202 07 30 +31 72 202 07 31 info@bioqcontrol.com www.bioqcontrol.com
More informationSupplementary Figure 1 MicroRNA expression in human synovial fibroblasts from different locations. MicroRNA, which were identified by RNAseq as most
Supplementary Figure 1 MicroRNA expression in human synovial fibroblasts from different locations. MicroRNA, which were identified by RNAseq as most differentially expressed between human synovial fibroblasts
More informationWHO GUIDELINE ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA
WHO/BS/0. ENGLISH ONLY 0 0 0 WHO GUIDELINE ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA NOTE: This document has been prepared for the purpose of
More informationConfirmatory Testing Algorithm. Routine Donor Testing Algorithm
Confirmatory Testing Algorithm Blood Confirmatory ABO/Rh Beckman Coulter PK-ABO/Rh Immucor NEO ABO/Rh Immucor NEO ABO/Rh Immucor Manual ABO/Rh Typing Immucor Manual ABO/Rh Typing Discrepancy Resolution
More informationSupplementary Figure 1 a
Supplementary Figure a Normalized expression/tbp (A.U.).6... Trip-br transcripts Trans Trans Trans b..5. Trip-br Ctrl LPS Normalized expression/tbp (A.U.) c Trip-br transcripts. adipocytes.... Trans Trans
More informationHIV-1 Seroconversion Panel PRB975
Seroconversion OVERVIEW is a five member HIV Seroconversion collected from a single donor over a 14 day period in 2002, prior to antibody seroconversion. -03 is a challenging sample for HIV RNA assays,
More informationCitation for published version (APA): Oosterveer, M. H. (2009). Control of metabolic flux by nutrient sensors Groningen: s.n.
University of Groningen Control of metabolic flux by nutrient sensors Oosterveer, Maaike IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it.
More informationRole and missions of a National Reference center for blood borne agents: the French example
Role and missions of a National Reference center for blood borne agents: the French example Virginie Sauvage, PhD Département des Agents Transmissibles par le Sang, Centre National de Référence pour les
More informationThe Food and Drug Administration (FDA) has
NAT Comparative analysis of triplex nucleic acid test assays in United States blood donors Susan L. Stramer, David E. Krysztof, Jaye P. Brodsky, Tracy A. Fickett, Benjamin Reynolds, Roger Y. Dodd, and
More informationNew HIV Tests and Algorithm: A change we can believe in
New HIV Tests and Algorithm: A change we can believe in Esther Babady, PhD, D (ABMM) Memorial Sloan-Kettering Cancer Center New York, New York Learning Objectives After this presentation you should be
More informationAssays to Address Emerging Threats to Blood Safety
Assays to Address Emerging Threats to Blood Safety Jeffrey M. Linnen, Ph.D. Director, Product Development Gen-Probe Incorporated San Diego, CA The IPFA/PEI 17th Workshop on Surveillance and Screening of
More informationEvaluation of external NAT controls from two manufacturers
Evaluation of external NAT controls from two manufacturers Aneta Kopacz, Institute of Hematology and Transfusion Medicine, Warsaw, Poland NAT and External QC in Poland (2018) SCREENING Regional Blood Transfusion
More informationP0141 HBV 1000 copies/ml genotype reference panel
P0141 HBV 1000 copies/ml genotype reference panel P0141 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents
More informationP0069 ViraQ HBV Trend 25 P0069
P0069 ViraQ HBV Trend 25 P0069 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3
More informationIn October 2005, the South African National Blood
DONOR INFECTIOUS DISEASE TESTING Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk_3355
More informationFigure S1. Analysis of genomic and cdna sequences of the targeted regions in WT-KI and
Figure S1. Analysis of genomic and sequences of the targeted regions in and indicated mutant KI cells, with WT and corresponding mutant sequences underlined. (A) cells; (B) K21E-KI cells; (C) D33A-KI cells;
More informationProposed 1 st IS for Hepatitis E Virus RNA WHO/BS/
www.pei.de Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/09.2126 S. Baylis, Division of Virology, Paul-Ehrlich-Institut, Langen, Germany SoGAT XXII 14 th -15 th April 2011, Rome, Italy Presented at:
More informationP0069 ViraQ HBV Trend 25 P0069
P0069 ViraQ HBV Trend 25 P0069 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3
More informationAbbreviations: P- paraffin-embedded section; C, cryosection; Bio-SA, biotin-streptavidin-conjugated fluorescein amplification.
Supplementary Table 1. Sequence of primers for real time PCR. Gene Forward primer Reverse primer S25 5 -GTG GTC CAC ACT ACT CTC TGA GTT TC-3 5 - GAC TTT CCG GCA TCC TTC TTC-3 Mafa cds 5 -CTT CAG CAA GGA
More informationto be notified: all parties involved in the graduated plan procedure. Annexes
Paul-Ehrlich-Institut Postfach 63207 Langen, Germany To all marketing authorisation holders of cellular blood preparations and therapeutic single plasmas as well as authorisation holders of stem cells
More informationRAPID BACTERIAL DETECTION METHODS FOR PLATELETS. M. Schmidt
RAPID BACTERIAL DETECTION METHODS FOR PLATELETS M. Schmidt Deutsches Rotes Kreuz Blutspendedienst Baden-Württemberg-Hessen Goethe Universität Frankfurt am Main Institut für Transfusionsmedizin und Immunhämatologie
More informationComplicated viral infections
Complicated viral infections Clinical case discussion Diagnostic dilemmas NSW State Reference Laboratory for HIV St Vincent s Hospital Sydney Diagnostic dilemmas Indeterminate or discordant serology (western
More informationAccuVert HIV-1 Seroconversion Panel PRB974 ( )
PACKAGE INSERT PRB974 (0600-0258) INTENDED USE PRB974 (0600-0258) is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers
More informationThe cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P Record Status This is a critical abstract of an economic evaluation that meets
More informationHIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg
HIV viral load testing in the era of ART Christian Noah Labor Lademannbogen, Hamburg 1 Life expectancy of patients on ART Data from the UK Collaborative HIV Cohort (UK CHIC) Requirements: Early diagnosis
More informationEXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2011
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2011 Collaborative Study to Evaluate the Proposed 3 rd WHO International Standard for Hepatitis B Virus (HBV) for Nucleic
More informationUvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication
UvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication Citation for published version (APA): Lieshout-Krikke, R. W. (2016). Residual
More informationP0154 ViraQ HBV Trend 50 P0154
P0154 ViraQ HBV Trend 50 P0154 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3
More informationPolicy # MI_MD_MPXNAT Department of Microbiology. Page Quality Manual
Department of Microbiology Version: 1.0 CURRENT 1 of 20 Prepared by QA Committee Issued by: Laboratory Manager Revision Date: 9/11/2017 Approved by Laboratory Director: Annual Review Date: 11/1/2018 Microbiologist-in-Chief
More informationHIV-1 Seroconversion Panel PRB973
A SERACARE PANEL PRODUCT INTENDED USE The is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers and clinical laboratorians
More informationSince 1973 all blood donations in the Netherlands
ORIGINAL RESEARCH Rare transmission of hepatitis B virus by Dutch donors with occult infection Ryanne W. Lieshout-Krikke, 1 Marian G.J. van Kraaij, 2 Fikreta Danovic, 2 and Hans L. Zaaijer 1 BACKGROUND:
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationWPTTID / Virology subgroup Activities
WPTTID / Virology subgroup 2010 2011 Activities Progress on previously launched collaborative Projects International Survey on NAT Testing of Blood Donations: Expanding Implementation and Yield from 1999
More informationWHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2016 WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA
More informationThe effect of lamivudine- versus tenofovir-containing antiretroviral regimen on hepatitis B infection in a cohort of HIV infected long term survivors
The effect of lamivudine- versus tenofovir-containing antiretroviral regimen on hepatitis B infection in a cohort of HIV infected long term survivors Aura Temereanca 1,2, Luminita Ene 3, Adelina Rosca
More informationISBT WP-TTID Annual Report for Subgroup on Virology Drs. Michael Busch, Kurt Roth and Susan Stramer
ISBT WP-TTID Annual Report for Subgroup on Virology Drs. Michael Busch, Kurt Roth and Susan Stramer Questionnaire on NAT Screening of Blood Donations for an International Forum on 10 years of NAT Screening
More informationISBT TTI WP HBV safety subgroup. Review and update
ISBT TTI WP HBV safety subgroup Review and update Distribution of dominant HBV genotypes countries & centres participating in HBV studies A2/A1 0.1-0.5 A2 D 0.1-8 B/C F 1-5 E 12-25 5-12 A1 4-8 A2/C HBV
More informationSUPPLEMENTARY INFORMATION
doi: 10.1038/nature05883 SUPPLEMENTARY INFORMATION Supplemental Figure 1 Prostaglandin agonists and antagonists alter runx1/cmyb expression. a-e, Embryos were exposed to (b) PGE2 and (c) PGI2 (20μM) and
More informationMolecular Diagnosis Future Directions
Molecular Diagnosis Future Directions Philip Cunningham NSW State Reference Laboratory for HIV/AIDS & Molecular Diagnostic Medicine Laboratory, SydPath St Vincent s Hospital Sydney Update on Molecular
More informationHBV PUBLIC HEALTH IMPLICATIONS
جزايری دکتر سيد محمد آزمايشگاه ھپاتيت B -دانشکده بھداشت ويروس شناسی- گروه دانشگاه علوم پزشکی تھران کنگره ارتقا کيفيت- ١٣٩٢ HBV PUBLIC HEALTH IMPLICATIONS 2 billion people have been infected by HBV worldwide.
More information